Inclusion Criteria:
1. Age range from 2 to 10 years old, female;
2. The clinical diagnosis of the subject is RTT, and after genetic testing, it was found to be a pathogenic variant of the MECP2 gene;
3. The legal guardian is able to understand the requirements and procedures of the research plan, voluntarily participate, and sign an informed consent form.
Exclusion Criteria:
1. Has participated in or is currently participating in other RTT drug clinical trials or other AAV gene therapy clinical studies;
2. The subject has a history of head injuries that can cause neurological disorders such as epilepsy, physical disabilities, etc;
3. The subject has MECP2 gene mutation but does not cause RTT;
4. Subjects with allergic constitution, including those allergic or hypersensitive to prednisolone, other glucocorticoids, their excipients, and local anesthetics;
5. The subjects had status epilepticus in the 3 months prior to enrollment;
6. Subjects require invasive or non-invasive ventilation support;
7. Serum anti AAV9 neutralizing antibody titer\>1:200;
The researchers believe that it is not suitable to participate in this study.
View Inclusion and Exclusion Criteria at ClinicalTrials.gov